Kornimate/medical-research-clean huggingface dataset:
study to eliminate hib carriage in rural alaska native villages

Conditions: Haemophilus Influenzae Type B; Carrier State

Summary: hib disease rates in rural alaska before introduction of hib conjugate vaccine were among the highest in the world. since vaccine introduction, rates have fallen by 90% but the disease has not been eliminated. this study is designed to test one possible means of eliminating hib carriage and thus to eliminate person to person transmission and invasive disease. the objective of this study is to evaluate the effectiveness of community-wide use of hib conjugate vaccine for eliminating oropharyngeal hib carriage in rural alaska villages. secondary objectives include: * determine risk factors for hib op carriage including demographic characteristics, and immunologic characteristics (antibody level and function). this will be accomplished through a case-control study described below. * measure antibody response to hib conjugate vaccine among adults who have not previously received hib vaccine. this will be accomplished through a cohort study of participating adults in the vaccine intervention communities.

this was a pilot intervention to assess the feasibility of using hib conjugate vaccine to eliminate hib carriage in rural alaska villages, with three villages to serve as a comparison group. we performed community-wide surveys of hib carriage by recruiting volunteers for throat cultures to establish a baseline rate of hib carriage for each community. then hib carriers were offered chemoprophylaxis to clear hib from their throats. in the vaccine intervention communities, a single dose of hib conjugate vaccine was offered to persons of all ages. this was followed by a second community-wide hib carriage survey after one year to assess the effectiveness of the intervention.

Eligibility criteria:
inclusion criteria: * all village residents are eligible for hib colonization survey * all residents of selected villages eligible for vaccine study except as noted below. exclusion criteria: * for receipt of vaccine: * history of allergic reaction to hib vaccine or components * age \< 24 months and not due for hib vaccine according to childhood immunization schedule * age \> 24 months and have received hib vaccine within past year * pregnant

Keywords: haemophilus influenza type b carrier state bacterial vaccines anti-prp antibody antibody avidity serum bacteriocidal antibody american indians/alaska natives case control study adult vaccines
comparing effect of hylorunic acid and lipid-coated carbomer gel on dry eyes after phacoemulsification in dp

Conditions: Dry Eye Syndrome

Summary: in this research checked the curative effect of two different artificial tears on dry eyes after phacoemulsification was checked. in research, the randomized control trial methodology is used


Eligibility criteria:
inclusion criteria: * patients aged 50-70 * both gender male /female exclusion criteria: * patients who have acute dry eye condition before phacoemulsification cataract surgery.
retention of bone marrow donors in a national registry

Conditions: Bone Marrow Transplantation; Blood Disease

Summary: to identify factors that affected the national marrow donor program's (nmdp) success in retention of bone marrow volunteers.

background: as bone marrow transplantation becomes one of the preferred treatments for life-threatening diseases of the blood, increasing numbers of patients must seek compatible marrow from unrelated donors. the low probability of finding a good patient-donor marrow match means that between one- to two-thirds of ill patients never locate a donor with perfectly compatible marrow. furthermore, once volunteers are identified as a preliminary match for a patient, 30 to 40 percent are either unwilling or medically unable to actually donate marrow. thus, volunteer attrition contributes significantly to the problems already inherent in finding a suitable donor candidate. design narrative: the study examined the relationship of volunteer characteristics and donor center factors to volunteer psychological outcomes during two critical stages in the blood testing process and to donor center rates of volunteer cooperation at these stages. longitudinal and cross-sectional survey data were gathered from a total of over 2,900 potential marrow donors who were at one of two critical decision points in the process leading to donation (dr-blood-typing, ct-blood-typing), and from personnel at the 100 nmdp donor centers. these data allowed the investigators to (a) describe the distribution and interrelationships between donor center structural characteristics and the strategies centers utilize for volunteer recruitment and retention, (b) determine which donor center factors (both structural and tactical) and volunteer background characteristics best predict positive volunteer-specific psychological outcomes at later typing stages, and examine and revise models of individual volunteer-specific outcomes and aggregate across-center retention rates. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
highlanders with high altitude pulmonary hypertension (haph), pulmonary arterial pressure (pap) assessed at 3200m with and without supplemental oxygen therapy (sot)

Conditions: High Altitude Pulmonary Hypertension

Summary: the investigators aim to study the effect of sot in highlanders with high altitude pulmonary hypertension (haph) who permanently live \>2500m on pulmonary arterial pressure (pap) assessed at 3200 m.

highlanders with haph diagnosed by echocardiography and defined by a rv/ra (tricuspid regurgitation pressure gradient) \>30 mmhg will be recruited for this project. highlanders permanently living at ha \>2500 m will have echocardiografy to assess pap near their living altitude in aksay at 3200 m with and without 10l/min supplemental oxygen therapy (sot) via face mask.

Eligibility criteria:
inclusion criteria: * permanently living \>2500 m * haph diagnosed with a minimum rv/ra of 30 mmhg assessed by echocardiography at an altitude of 3200 m * written informed consent exclusion criteria: * highlanders who cannot follow the study investigations, * patients with moderate to severe concomitant lung disease (fev1\ 20 cigarettes/day or \>20 pack-years. * coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Keywords: pulmonary hypertension hypoxia high altitude supplemental oxygen therapy pulmonal arterial pressure
effect of chuna manipulation therapy on gait in patients with lumbar disc herniation

Conditions: Lumbar Disc Herniation; Gait Analysis; Manual Therapy

Summary: prospective observation study of the effect of chuna manipulation therapy on gait in patients with lumbar disc herniation

to investigate the effect of chuna manual therapy on gate, 20 patients with lumbar disc herniation were studied. the gait analysis was performed before the first treatment, after the seventh treatment, after the 14th treatment, and compared with the data of 20 normal subjects.

Eligibility criteria:
inclusion criteria: * lumbar intervertebral disc herniation as confirmed by a doctor of medicine or a doctor of korean medicine through an mri * patients with radiculopathy * patients aged 19 to 60 * patients with an oswestry disability index (odi) of ≥10 * patients who have agreed to participate in the clinical study and given written informed consent exclusion criteria: * patients who were unable to walk for more than 5 minutes due to pain * patients with a serious disease that may limit gait(such as spinal metastasis of the tumor, acute fracture and spinal dislocation) * patients with chronic conditions that may interfere with the interpretation of the therapeutic effect or outcome(such as chronic kidney failure) * patients with progressive neurological deficit or severe neurological symptoms such as spinal cord injury * patients with severe mental illness * patients who are currently on on steroids, immunosuppressants, psychiatric medications, or other medications that can affect outcome * patients who are pregnant or planning a pregnancy * patients who are participating in other clinical studies or if it is difficult for you to participate in clinical research as determined by the researcher

Keywords: gait effectiveness treatment lumbar intervertebral disc herniation chuna
the optimal dose of mannitol for intraoperative brain relaxation during the operation of aneurysmal subarachnoid hemorrhage

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: aneurysmal subarachnoid hemorrhage (asah) tended to lead to a sudden increase in intracerebral pressure (icp), which can cause decreased cerebral perfusion and transient global cerebral ischemia. early clipping and coiling of aneurysms and surgical evacuation of intracerebral hematoma were recommended for asah patients. however, the high icp made it difficult to separate the subarachnoid space during the operation. effective reduction of icp was the key to the succession of the operation. but there is a lack of consensus on the management of raised icp in asah. mannitol is widely used to reduce icp in patients with cerebral edema. the potential mechanism including decreasing the viscosity of the blood improving regional cerebral microvascular flow and oxygenation and increasing intravascular volume due to increased plasma osmolality. the magnitude of the pressure reduction was correlated with the intact intracranial automatic adjustment function. however, the hypochloremic metabolic alkalosis, hypernatremia, hypokalemia and renal failure associated with mannitol overdose must be considered and the effective dose and the duration of its administration were still unknown. the aims of this study were to determine the most appropriate mannitol dose to provide adequate brain relaxation in asah patients with the fewest adverse effects.


Eligibility criteria:
inclusion criteria: * patients with acute subarachnoid hemorrhage * patients who underwent frontal-temporal craniotomy pterional approach aneurysm clipping surgery under general anesthesia. * patients operated by the same surgeon (dr. chen xiaolin). exclusion criteria: * patients who do not agree to the surgery. * patients who have congestive heart failure and kidney insufficiency. * patients who have pre-operative electrolyte imbalance. * patients who did not take the frontotemporal pterygoid approach. * patients with contraindications to mannitol due to low blood pressure. * patients who have had more than 3 days from bleeding to surgery. * patients with intracranial hematoma. * patients with hunt-hess grades 4-5. * patients who received intravenous mannitol within 6 hours before surgery. * patients who underwent ventricle puncture and drainage surgery before surgery.
administration of prothrombin complex concentrate vs. standard transfusion during/after heart transplantation

Conditions: Heart Disease End Stage; Heart Failure，Congestive

Summary: this study is comparing the use of kcentra vs. standard transfusion in patients undergoing heart transplantation surgery. half of the patients will receive kcentra, while the other half will receive fresh frozen plasma.

this study will be a randomized (1:1; pcc vs. plasma), open-label trial of hemostatic therapies during heart transplantation. the goal is to enroll 60 patients. informed consent will be obtained from patients meeting the inclusion and exclusion criteria before the initiation of any study specific procedures. eligible patients will be randomized to receive either pcc or plasma transfusion. the efficacy of interventions will be evaluated after 30 minutes of protamine administration. after the heart transplantation, thrombocytopenia and/or hypofibrinogenemia may worsen bleeding associated with vitamin k dependent factor deficiencies. transfusion of platelets and/or cryoprecipitate is permitted if abnormal laboratory values are observed during the rewarming phase of cpb; platelet count \<100 x 103/µl, and fibrinogen \<200 mg/dl, respectively. laboratory tests (hematocrit, platelet count, pt, ptt, poc-pt, coagulation factor and inhibitor levels (e.g., factor ii, antithrombin), thromboelastometry or thromboelastography, endogenous thrombin generation) will also be obtained at baseline, twice during surgery and at 12-24 hours after surgery.

Eligibility criteria:
inclusion criteria: * be willing and able to provide written informed consent. * be at least 18 years of age. * patients with or without ventricular assist device (vad) undergoing heart transplantation * patients who have been on warfarin for at least 72 hours before cardiopulmonary bypass procedures for heart transplantation. * international normalization ration (inr) greater than or equal to 1.5 * body temperature greater than 35.0 degrees celsius. * blood ph greater than 7.2 * hemoglobin greater than 7.0 mg/dl. exclusion criteria: * treatment with clopidogrel, prasugrel, or ticagrelor within 5 days prior to study surgery. * known or suspected thrombophilia such as factor v leiden, hereditary antithrombin iii deficiency, heparin-induced thrombocytopenia, disseminated intravascular coagulation. * ischemic or thromboembolic events within 6 weeks of study surgery. * known allergy/anaphylaxis to prothrombin complex concentrate or albumin. * any indication that a potential subject did not comprehend the study restrictions, procedures. or consequences therein an informed consent cannot be convincingly given. * patients on respiratory support including extracorporeal membrane oxygenation (ecmo) . * life expectancy less than 48 hours. * excluded at the discretion of the surgeon based upon surgical safety precautions

Keywords: heart transplantation
the bifsorb pilot study ii

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to investigate the feasibility and safety of the magmaris brs for treatment of coronary bifurcation lesions.

bioresorbable stents are promising in treatment of coronary artery disease. the concept of bifurcation treatment using brs is particular appealing as struts covering the side branch ostium may resorb over time. the aim of this study is to investigate the feasibility and safety of the magmaris brs for treatment of coronary bifurcation lesions. hypothesis: treatment of coronary bifurcation lesions using the magmaris brs is safe and feasible. methods: the study is a proof-of-concept, prospective, single arm study with inclusion of 20 patients. planned 1-and 12-month follow-up by optical coherence tomography (oct) and follow-up for clinical endpoints until 5 years. written informed consent is required before the procedure is performed. eligible patients with a bifurcation lesion are treated by the provisional technique with mandatory jailing of the side branch and provisional opening of side branch ostium by the mini-kiss technique in case of severe pinching or timi-flow less than iii. proximal post-dilatation is mandatory. no dilatation beyond the expansion limits of the stent. at baseline, the target lesion is assessed by oct before, during and after implantation of the magmaris brs. oct assessment is performed again at 1- and 12-month follow-up, or before if the patient is readmitted with a possible target lesion failure. the operator is not blinded to the oct images as pre-pci images should be used for sizing and positioning of the stent, and procedural oct images are used to optimize stent implantation before performing final oct.

Eligibility criteria:
inclusion criteria: * stable angina pectoris * stabilized non-st elevation myocardial infarction * silent angina pectoris * age \> 18 years * de novo coronary bifurcation lesion at lad/diagonal, cx/obtuse marginal or rca-pda/posterolateral branch * all medina classes except medina x.x.1. * diameter of side branch ≥ 2.5 mm * side branch diameter stenosis less than 50% * signed informed consent exclusion criteria: * st-elevation infarction within 48 hours * expected survival \< 1 year * severe heart failure (nyha≥iii) * s-creatinine \> 120 µmol/l or gfr \< 0.45 ml/min per 1.73 m2 * allergy to contrast media, aspirin, clopidogrel, ticagrelor, ticlopidine or sirolimus * unable to cover main vessel lesion with one stent * severe tortuosity * severe calcification

Keywords: percutaneous intervention (pci) optical coherence tomography (oct) bifurcation lesion bioresorbable stents (brs)
high dose camptothecin-11 (cpt-11) in recurrent unresectable malignant glioma

Conditions: Malignant Glioma

Summary: the purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.

this is a phase i/ii study of high dose irinotecan in patients with recurrent unresectable malignant glioma on steroids/anti-epileptics. the purpose is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.

Eligibility criteria:
inclusion criteria: * recurrent, unresectable primary cns neoplasm per mri * ecog status of 2 or less * no prior therapy with camptothecans * on an enzyme-inducing antiepileptic

Keywords: high dose irinotecan cpt-11 camptosar malignant glioma unresectable
cfdna methylation assay for clinical evaluation of patients with stage ia lung cancer after ablation operation

Conditions: Lung Cancer

Summary: the objective is to screen and monitor the efficacy of cfdna methylation in patients with stage i lung cancer after ablation, to compare the similarities and differences of cfdna methylation between surgical treatment and ablation in patients with stage i lung cancer, and to look for new indicators to assess the efficacy of ablation therapy and to monitor lung cancer recurrence.

the objective is to screen and monitor the efficacy of cfdna methylation in patients with stage i lung cancer after ablation, to compare the similarities and differences of cfdna methylation between surgical treatment and ablation in patients with stage i lung cancer, and to look for new indicators to assess the efficacy of ablation therapy and to monitor lung cancer recurrence. the main research content is to screen the cfdna methylation index that can monitor the efficacy of stage i lung cancer ablation and compare the similarities and differences of cfdna methylation in patients with stage i lung cancer after surgery and ablation.

Eligibility criteria:
inclusion criteria: 1. age: 18-85 years old; 2. the peripheral pulmonary nodules found in patients with chest ct, preoperative examination showed that the clinical stage of patients was t1n0m0, ia; 3. patients are not suitable for surgical treatment through multidisciplinary assessment, agree to accept ablation 4. patients have good compliance with the tests and follow-ups, understand the situation of the study and sign informed consent. exclusion criteria: 1. the patient is generally in poor condition and cannot tolerate the examination; 2. patients with a cardiac pacemaker or stent in the heart; peripheral tumors of the lungs are adjacent to large blood vessels or important structures; 3. patients with poor compliance; 4. researchers believe that it is not appropriate to participate in this trial.

Keywords: ablation circulating free dna methylation
reducing sedentary time in patients with cardiovascular disease

Conditions: Cardiovascular Diseases; Heart Diseases; Sedentary Behavior; Physical Activity

Summary: the purpose of this study is to develop and test a 12-week sedentary behavior reduction intervention ("sit less" program) for patients with cardiovascular disease. the program aims to reduce and break sitting times among this population using an objective activity monitor and mhealth. the investigators will test the program to help cardiovascular disease patients break up sitting time, reduce daily sitting time, and move more. the investigators will also study whether the program leads to improvements in heart disease risk factors, and whether cardiovascular disease patients like the program and can follow it.

the investigators propose to develop and conduct a pilot 2-arm rct to test a wearable technology-based sedentary behavior reduction intervention in cardiovascular disease patients. participants will be randomized to either the control group or the sedentary behavior reduction intervention group. the intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mhealth. specifically, the study aims to: determine the feasibility and acceptability of the sedentary behavior reduction intervention in cardiovascular patients by evaluating reach, retention, satisfaction, and compliance with the intervention; evaluate the preliminary efficacy of the sedentary behavior reduction intervention on changes in sedentary time; and explore preliminary effects of the sedentary reduction intervention on physical activity, cardiometabolic markers and patient-centered outcomes.

Eligibility criteria:
inclusion criteria: * ages 18 and above * have at least one of the following conditions including history of heart attack or peripheral artery disease or a stent placed in heart or leg * self-report of sitting ≥ 8 hr/day * ability to stand and walk * ownership of a smartphone exclusion criteria: * currently using an activity tracker * currently participating in exercise of cardiac rehabilitation programs * non-english speaking * patients who are classified as unstable (e.g. heart failure, uncontrolled arrhythmia) or have kidney disease that limits daily water intake, or any other conditions contradictory to standing or walking and * currently pregnant

Keywords: sedentary behavior cardiovascular disease
effects of different fresh gas flows on carboxyhemoglobin levels

Conditions: Fresh Flow; Carboxyhemoglobinemia

Summary: to observe the effect of different fresh flows (1 l / min and 4 l / min) on the carboxyhemoglobin level non-invasively and continuous measurement and to determine the contribution of smoking to the intraoperative carbon monoxide accumulation.


Eligibility criteria:
inclusion criteria: * asa i-ii * undergo 2-4 hours of elective surgery exclusion criteria: * cardiovascular disease * diabetes mellitus * kidney, liver failure * chronic obstructive pulmonary disease * patients with opioid sensitivity * morbidly obese * personal or family history of malignant hyperthermia * history of prolonged recovery from anesthesia * alcohol addicted * pregnant and breastfeeding women patients allergic to study drugs

Keywords: low flow anesthesia non-invasive carboxyhemoglobinemia monitoring smoking